


JPW



17525(AP)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Atassi)
Serial No.: 10/821,669)
Conf. No.: 9880)
Filed: April 8, 2004)
For: BOTULINUM TOXIN A PEPTIDES)
AND METHODS OF PREDICTING)
AND REDUCING IMMUNO-)
RESISTANCE TO BOTULINUM)
TOXIN THERAPY)

Group Art Unit: Applied for

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Mail Stop Supplemental Information Disclosure Statement, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date of Deposit: 4/22/05

Bonnie Ferguson
Print Name

Signature: Bonnie Ferguson

Date of Signature: 4/22/05

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents
Alexandria, VA 22313-1450

Sir:

The references listed on the attached PTO-1449 form are being brought to the attention of the Examiner under 37 C.F.R. §1.97(c) for consideration in connection with the examination of the above-identified patent application. None of these publications are admitted to be prior art to the presently claimed invention, but are deemed of sufficient relevance to be brought to the attention of the Examiner.


Each item of information contained in this Supplemental Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO-1449 form with initials or other appropriate marks.

No fee is believed due in connection with this communication in accordance with 37 C.F.R. § 1.97(c) and 37 C.F.R. § 1.97(e). However, if Applicant is in error, please charge any fees that may be due in connection with this Information Disclosure Statement to Deposit Account No. 01-0885.

Respectfully submitted,

Date: 4/22/05


Dean G. Stathakis
Registration No. 54,465

ALLERGAN, INC.
Legal Department-T2-7H
2525 Dupont Drive
Irvine, CA 92612
Telephone: (714) 246-6521
Facsimile: (714) 246-4249
April 22, 2005



LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET: 17525(BOT)	SERIAL NO.: 10/821,669
APPLICANT: Atassi	TITLE: BOTULINUM TOXIN A PEPTIDES AND METHODS OF PREDICTING AND REDUCING IMMUNORESISTANCE TO BOTULINUM TOXIN THERAY
FILING DATE: APRIL 9, 2004	GROUP: APPLIED FOR

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
BC	2002/0197278	26 Dec. 2002	Allison			

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

BD	Singh et al, "Immunochemical characterization of Type A botulinum neurotoxin in its purified and complexed forms.", Toxicon, 1996, Vol. 36, No. 2, pages 267-275
----	--

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.